Genta Incorporated to Present in Roundtable and Corporate Sessions At Bio Ceo & Investor Conference
BERKELEY HEIGHTS, N.J., Feb 21, 2003 /PRNewswire-FirstCall via COMTEX/ -- Genta
Incorporated (Nasdaq: GNTA) today announced its participation at the
Biotechnology Industry Organization (BIO) CEO & Investor Conference in New York,
NY. Raymond P. Warrell, Jr., M.D., Chairman and Chief Executive Officer, will
make a presentation on Thursday, February 27 at 10:00 a.m. EST that will feature
clinical overviews and updates on the Company's Genasense(TM) (oblimersen
sodium) and Ganite(TM) (gallium nitrate injection) programs.
The Genta corporate presentation can be accessed via the web through Genta's
investor site at: genta.com . A replay will be available
for 30 days following the presentation.
In addition to the Corporate presentation, Dr. Warrell will participate in a CEO
Roundtable entitled "Cancer Therapies: What's Working Now and What's on the
Horizon?" sponsored by Banc of America. The panel will take place on Wednesday,
February 26, 2003 at 2:00 p.m. and will not be webcast.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product
portfolio that is focused on anticancer therapy. The Company's research platform
is anchored by oligonucleotide chemistry, particularly applications of antisense
and decoy aptamer technology. Genasense(TM), the Company's lead compound, is
being developed in collaboration with Aventis and is currently undergoing
late-stage, Phase 3 clinical testing in several clinical indications. Genta's
pipeline also comprises a portfolio of small molecules, including
gallium-containing compounds and Androgenics compounds for prostate cancer, as
well as an anticancer series of DNA-based compounds called "decoy aptamers." For
more information about Genta, please visit our website at: genta.com
This press release and the webcast to follow contain forward-looking statements
with respect to business conducted by Genta Incorporated. By their nature,
forward-looking statements and forecasts involve risks and uncertainties because
they relate to events and depend on circumstances that will occur in the future.
There are a number of factors that could cause actual results and developments
to differ materially. For a discussion of those risks and uncertainties, please
see the Company's Annual Report/Form 10-K for 2001.
SOURCE Genta Incorporated
CONTACT: Tara Spiess, Director, Investor Relations and Corporate
Communications of Genta Incorporated, +1-908-286-3980 |
